0001493152-20-000994.txt : 20200123 0001493152-20-000994.hdr.sgml : 20200123 20200123171530 ACCESSION NUMBER: 0001493152-20-000994 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200115 FILED AS OF DATE: 20200123 DATE AS OF CHANGE: 20200123 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: 1315 Capital II, L.P. CENTRAL INDEX KEY: 0001730825 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 000-24249 FILM NUMBER: 20543009 BUSINESS ADDRESS: STREET 1: 2929 WALNUT STREET STREET 2: SUITE 1240 CITY: PHILADELPHIA STATE: PA ZIP: 19104 BUSINESS PHONE: 215-662-1315 MAIL ADDRESS: STREET 1: 2929 WALNUT STREET STREET 2: SUITE 1240 CITY: PHILADELPHIA STATE: PA ZIP: 19104 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: INTERPACE BIOSCIENCES, INC. CENTRAL INDEX KEY: 0001054102 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 222919486 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: MORRIS CORPORATE CENTER 1, STREET 2: BUILDING C, 300 INTERPACE PARKWAY CITY: PARSIPPANY STATE: NJ ZIP: 07054 BUSINESS PHONE: 412-224-6100 MAIL ADDRESS: STREET 1: MORRIS CORPORATE CENTER 1, STREET 2: BUILDING C, 300 INTERPACE PARKWAY CITY: PARSIPPANY STATE: NJ ZIP: 07054 FORMER COMPANY: FORMER CONFORMED NAME: Interpace Diagnostics Group, Inc. DATE OF NAME CHANGE: 20151223 FORMER COMPANY: FORMER CONFORMED NAME: PDI INC DATE OF NAME CHANGE: 20021113 FORMER COMPANY: FORMER CONFORMED NAME: PROFESSIONAL DETAILING INC DATE OF NAME CHANGE: 19980129 3 1 ownership.xml X0206 3 2020-01-15 0 0001054102 INTERPACE BIOSCIENCES, INC. IDXG 0001730825 1315 Capital II, L.P. C/O INTERPACE BIOSCIENCES, INC. 300 INTERPACE PARKWAY PARSIPPANY NJ 07054 0 0 1 0 Series B Convertible Preferred Stock 6.00 Common Stock 3166666 D The Series B Convertible Preferred Stock, par value $0.01 per share, of the Issuer (the "Series B") is convertible from time to time, at the option of the holder thereof, into a number of shares of common stock, par value $0.01 per share, of the Issuer (the "Common Stock"), equal to the initial stated value per Series B share of $1,000 (subject to adjustment) divided by an initial conversion price of $6.00 per share (subject to adjustment) and then multiplied by the number of shares of Series B to be converted. The Series B has no expiration date. These securities are held of record by the Reporting Person. 1315 Capital Management II, LLC ("1315 Capital Management") is the general partner of the Reporting Person. By virtue of such relationship, 1315 Capital Management may be deemed to have voting and investment power with respect to the securities held by the Reporting Person noted above and as a result may be deemed to have beneficial ownership over such securities. Each of the Reporting Person and 1315 Capital Management disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its or his pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for the purpose of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. By 1315 Capital Management II, LLC, its sole general partner, By: Adele C. Oliva, Managing Member /s/ Adele C. Oliva 2020-01-23